Last reviewed · How we verify
NCT07294911: PC-AKI-ACS
Predictors of Contrast-induced Acute Renal Injury in Patients With Acute Coronary Syndrome
trial testing Observational data collection in Acute Coronary Syndrome in 88 participants. Completed in 2 September 2025.
2 June 2025
Quick facts
| Lead sponsor | Karaganda Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 88 |
| Start date | 2 November 2024 |
| Primary completion | 2 June 2025 |
| Estimated completion | 2 September 2025 |
| Sites | 1 location across Kazakhstan |
Drugs / interventions tested
- Observational data collection
Conditions studied
- Acute Coronary Syndrome — all drugs for Acute Coronary Syndrome →
- Contrast-Induced Acute Kidney Injury — all drugs for Contrast-Induced Acute Kidney Injury →
Sponsor
Karaganda Medical University
Who can join
18 and older, any sex, with Acute Coronary Syndrome or Contrast-Induced Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This observational study aims to identify predictors of contrast-induced acute kidney injury (CI-AKI) in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Clinical, laboratory, and procedural factors will be analyzed to determine their association with the development of CI-AKI. The findings may help improve risk stratification and preventive strategies in this high-risk population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07294911
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Coronary Syndrome
Currently open trials in the same condition.
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
- NCT07032389 — A Polypill for Acute Coronary Syndrome · Phase 2 · recruiting
- NCT07102628 — Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronar · Phase 3 · recruiting
- NCT06416813 — Preventive Intervention Value of DCB in Vulnerable Coronary Atherosclerotic Plaques · NA · active not recruiting
Other Karaganda Medical University trials
Trials by the same sponsor.
- NCT06460753 — Analysis of Laboratory Markers for Severe COVID-19 · completed
- NCT06937346 — Rehabilitation Robotic System ReHand · NA · completed
- NCT06221293 — Correlation Between Intra-abdominal Pressure, Biomarkers of Bacterial Translocation and Intestinal Wall Damage · active not recruiting
- NCT05222893 — Optimization of PEEP During Laparoscopic Surgery · NA · completed
- NCT04871841 — Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07294911 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Karaganda Medical University
- Last refreshed: 19 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07294911.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing